Literature DB >> 27190319

Virus and Host Testing to Manage Chronic Hepatitis B.

Grace Lai-Hung Wong1, Vincent Wai-Sun Wong1, Henry Lik-Yuen Chan1.   

Abstract

Chronic hepatitis B virus (HBV) infection is a major cause of cirrhosis and hepatocellular carcinoma worldwide. The past 50 years have seen rapid developments in HBV testing. Beginning from traditional serologic tests, the availability of sensitive HBV DNA assays allows a thorough understanding of the virology and natural history of chronic HBV infection. Quantification of hepatitis B surface antigen levels reflects the amount and transcriptional activities of covalently closed circular DNA in the liver and may be used to evaluate the stage of disease and guide antiviral therapy. The natural history of chronic HBV infection is also a manifestation of the interaction between the host and the virus, and recent genomic works have shed light on the host-virus relationship and may provide novel tests in the future. This review highlights recent advances in the application of HBV tests in the management of chronic hepatitis B.
© The Author 2016. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail journals.permissions@oup.com.

Entities:  

Keywords:  cirrhosis; hepatitis B e antigens; hepatitis B surface antigens; hepatocellular carcinoma; peginterferon alfa

Mesh:

Substances:

Year:  2016        PMID: 27190319      PMCID: PMC4889896          DOI: 10.1093/cid/ciw024

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  76 in total

Review 1.  Hepatitis B virus infection.

Authors:  Christian Trépo; Henry L Y Chan; Anna Lok
Journal:  Lancet       Date:  2014-06-18       Impact factor: 79.321

Review 2.  American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy.

Authors:  Robert P Perrillo; Robert Gish; Yngve T Falck-Ytter
Journal:  Gastroenterology       Date:  2014-10-31       Impact factor: 22.682

3.  Serum hepatitis B surface antigen levels predict surface antigen loss in hepatitis B e antigen seroconverters.

Authors:  Tai-Chung Tseng; Chun-Jen Liu; Tung-Hung Su; Chia-Chi Wang; Chi-Ling Chen; Pei-Jer Chen; Ding-Shinn Chen; Jia-Horng Kao
Journal:  Gastroenterology       Date:  2011-04-28       Impact factor: 22.682

4.  Kinetics of hepatitis B surface antigen differ between treatment with peginterferon and entecavir.

Authors:  Jurriën G P Reijnders; Vincent Rijckborst; Milan J Sonneveld; Sandra M J Scherbeijn; Charles A B Boucher; Bettina E Hansen; Harry L A Janssen
Journal:  J Hepatol       Date:  2010-11-05       Impact factor: 25.083

5.  Occult hepatitis B virus infection in chronic liver disease: full-length genome and analysis of mutant surface promoter.

Authors:  Vaishali Chaudhuri; Ruchi Tayal; Baibaswata Nayak; Subrat Kumar Acharya; Subrat Kumar Panda
Journal:  Gastroenterology       Date:  2004-11       Impact factor: 22.682

6.  Alanine aminotransferase-based algorithms of liver stiffness measurement by transient elastography (Fibroscan) for liver fibrosis in chronic hepatitis B.

Authors:  H L-Y Chan; G L-H Wong; P C-L Choi; A W-H Chan; A M-L Chim; K K-L Yiu; F K-L Chan; J J-Y Sung; V W-S Wong
Journal:  J Viral Hepat       Date:  2008-07-28       Impact factor: 3.728

7.  Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa.

Authors:  Erik H C J Buster; Bettina E Hansen; George K K Lau; Teerha Piratvisuth; Stefan Zeuzem; Ewout W Steyerberg; Harry L A Janssen
Journal:  Gastroenterology       Date:  2009-09-06       Impact factor: 22.682

8.  Meta-analysis: Treatment of hepatitis B infection reduces risk of hepatocellular carcinoma.

Authors:  J J Y Sung; K K F Tsoi; V W S Wong; K C T Li; H L Y Chan
Journal:  Aliment Pharmacol Ther       Date:  2008-07-24       Impact factor: 8.171

9.  Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study.

Authors:  Hyeon Chang Kim; Chung Mo Nam; Sun Ha Jee; Kwang Hyub Han; Dae Kyu Oh; Il Suh
Journal:  BMJ       Date:  2004-03-17

10.  Treatment cessation of entecavir in Asian patients with hepatitis B e antigen negative chronic hepatitis B: a multicentre prospective study.

Authors:  Wai-Kay Seto; Aric Josun Hui; Vincent Wai-Sun Wong; Grace Lai-Hung Wong; Kevin Sze-Hang Liu; Ching-Lung Lai; Man-Fung Yuen; Henry Lik-Yuen Chan
Journal:  Gut       Date:  2014-05-15       Impact factor: 23.059

View more
  6 in total

Review 1.  A roadmap for serum biomarkers for hepatitis B virus: current status and future outlook.

Authors:  Anna Kramvis; Kyong-Mi Chang; Maura Dandri; Patrizia Farci; Dieter Glebe; Jianming Hu; Harry L A Janssen; Daryl T Y Lau; Capucine Penicaud; Teresa Pollicino; Barbara Testoni; Florian Van Bömmel; Ourania Andrisani; Maria Beumont-Mauviel; Timothy M Block; Henry L Y Chan; Gavin A Cloherty; William E Delaney; Anna Maria Geretti; Adam Gehring; Kathy Jackson; Oliver Lenz; Mala K Maini; Veronica Miller; Ulrike Protzer; Jenny C Yang; Man-Fung Yuen; Fabien Zoulim; Peter A Revill
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2022-07-20       Impact factor: 73.082

2.  Effect of comprehensive nursing on the pain, anxiety and malnutrition of hepatitis B patients.

Authors:  Feifei Chen; Xiaoqun Pang; Xiaoling Dai
Journal:  Am J Transl Res       Date:  2021-05-15       Impact factor: 4.060

3.  Regulation of Molecular Chaperone GRP78 by Hepatitis B Virus: Control of Viral Replication and Cell Survival.

Authors:  Wangqin Shu; Zhiwei Guo; Lijie Li; Zhiqi Xiong; Ziyu Wang; Yuanyuan Yang; Yuqi Li; Minjing He; Ruijie Gong; Bo Gao
Journal:  Mol Cell Biol       Date:  2020-01-16       Impact factor: 4.272

4.  Comparison of Serum Hepatitis B Virus RNA Levels and Quasispecies Evolution Patterns between Entecavir and Pegylated-Interferon Mono-treatment in Chronic Hepatitis B Patients.

Authors:  Xiao-Qi Yu; Ming-Jie Wang; De-Min Yu; Pei-Zhan Chen; Ming-Yu Zhu; Wei Huang; Yue Han; Qi-Ming Gong; Xin-Xin Zhang
Journal:  J Clin Microbiol       Date:  2020-08-24       Impact factor: 5.948

5.  Comparative efficacy of the front-line anti-HBV drugs in nucleos(t)ide analogue-naive chronic hepatitis B: A protocol for systematic review and network meta-analysis.

Authors:  Mao-Bing Chen; Hua Wang; Qi-Han Zheng; Wei-Yan Cui; Hua-Lan Xu; Xu-Wen Zheng
Journal:  Medicine (Baltimore)       Date:  2020-05       Impact factor: 1.889

6.  ERK1/2-HNF4α axis is involved in epigallocatechin-3-gallate inhibition of HBV replication.

Authors:  Zi-Yu Wang; Yu-Qi Li; Zhi-Wei Guo; Xing-Hao Zhou; Mu-Dan Lu; Tong-Chun Xue; Bo Gao
Journal:  Acta Pharmacol Sin       Date:  2019-09-25       Impact factor: 6.150

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.